

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Life360, Inc.
ARBN:	629 412 942

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Synge
Date of last notice	17 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	20 June 2024 (PDT) (being 21 June 2024 AEST)
No. of securities held prior to change	<ul style="list-style-type: none">720,519 Chess Depositary Interests (CDIs)43,398 Shares of Common Stock (Shares)(equivalent to 130,194 CDIs)3,966 Shares held by ICCA Labs, LLC¹(equivalent to 11,898 CDIs)21,720 CDIs held by Stynge Pty Ltd ATF Sandy Bay Trust.8,373 Restricted Stock Units (RSUs)33,972 Options over Shares (Options)

¹ James Synge is a member of ICCA Labs, LLC, an entity that holds Life360 CDIs. The number of Shares attributable to James Synge by reason of his membership interest in ICCA Labs, LLC is 3,966.

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Class	Shares & RSUs
Number acquired	2,377 Shares
Number disposed	2,377 RSUs (having vested)
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Shares are issued following the vesting and settlement of 2,377 RSUs which were granted in lieu of the payment of Board and Committee Fees ² .
No. of securities held after change	<ul style="list-style-type: none"> • 720,519 CDIs • 45,775 Shares (equivalent to 137,325 CDIs) • 3,966 Shares held by ICCA Labs, LLC (equivalent to 11,898 CDIs) • 211,720 CDIs held by Styngge Pty Ltd ATF Sandy Bay Trust. • 5,996 RSUs • 33,972 Options
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Shares following the vesting and settlement of RSUs.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A

² As per the Appendix 3Y lodged with the ASX on 7 June 2023, 9,508 RSUs were granted in lieu of the payment of US\$125,500 of Board and Committee Fees.

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only